Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
Surgery Partners Inc (NASDAQ: SGRY) closed the day trading at $15.74 down -1.81% from the previous closing price of $16.03. In other words, the price has decreased by -$1.81 from its previous closing price. On the day, 7.69 million shares were traded. SGRY stock price reached its highest trading level at $16.5 during the session, while it also had its lowest trading level at $15.65.
Ratios:
For a better understanding of SGRY, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 9.92 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 10.40. For the most recent quarter (mrq), Quick Ratio is recorded 1.72 and its Current Ratio is at 1.88. In the meantime, Its Debt-to-Equity ratio is 2.24 whereas as Long-Term Debt/Eq ratio is at 2.15.
On December 16, 2024, BofA Securities started tracking the stock assigning a Buy rating and target price of $30.BofA Securities initiated its Buy rating on December 16, 2024, with a $30 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Oct 24 ’25 when Wayne DeVeydt bought 2,913 shares for $22.30 per share.
Wayne DeVeydt bought 30,948 shares of SGRY for $666,210 on Oct 23 ’25. On Oct 22 ’25, another insider, Wayne DeVeydt, who serves as the former director of the company, bought 25,052 shares for $21.27 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SGRY now has a Market Capitalization of 2036486272. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.61 while its Price-to-Book (P/B) ratio in mrq is 1.17.
Stock Price History:
The Beta on a monthly basis for SGRY is 1.94, which has changed by -0.37129974 over the last 52 weeks, in comparison to a change of 0.14151978 over the same period for the S&P500. Over the past 52 weeks, SGRY has reached a high of $31.89, while it has fallen to a 52-week low of $15.95. The 50-Day Moving Average of the stock is -26.26%, while the 200-Day Moving Average is calculated to be -30.42%.
Shares Statistics:
Over the past 3-months, SGRY traded about 1.41M shares per day on average, while over the past 10 days, SGRY traded about 1872690 shares per day. A total of 129.02M shares are outstanding, with a floating share count of 75.98M. Insiders hold about 40.74% of the company’s shares, while institutions hold 73.65% stake in the company. Shares short for SGRY as of 1761868800 were 13658832 with a Short Ratio of 10.08, compared to 1759190400 on 12278805. Therefore, it implies a Short% of Shares Outstanding of 13658832 and a Short% of Float of 22.29.
Earnings Estimates
The dynamic stock of Surgery Partners Inc (SGRY) is currently being evaluated by a team of 5.0 analysts, each contributing to its current rating.The consensus estimate for the next quarter is $0.03, with high estimates of $0.18 and low estimates of -$0.04.
Analysts are recommending an EPS of between $0.69 and $0.58 for the fiscal current year, implying an average EPS of $0.67. EPS for the following year is $0.91, with 10.0 analysts recommending between $1.65 and $0.69.
Revenue Estimates
11 analysts predict $884.46M in revenue for. The current quarter. It ranges from a high estimate of $931M to a low estimate of $863M. As of. The current estimate, Surgery Partners Inc’s year-ago sales were $864.4MFor the next quarter, 11 analysts are estimating revenue of $830.68M. There is a high estimate of $854M for the next quarter, whereas the lowest estimate is $805.8M.
A total of 11 analysts have provided revenue estimates for SGRY’s current fiscal year. The highest revenue estimate was $3.37B, while the lowest revenue estimate was $3.29B, resulting in an average revenue estimate of $3.31B. In the same quarter a year ago, actual revenue was $3.11BBased on 11 analysts’ estimates, the company’s revenue will be $3.6B in the next fiscal year. The high estimate is $3.67B and the low estimate is $3.44B.
